To understand why fusion with CCL11 enhanced antitumor activity, specific CD8 + T cells in the peripheral blood, secondary lymphoid tissues, and tumors of TC-1 tumor-bearing mice were analyzed 14 days after CCL11-E6E7 or E6E7 immunization using flow cytometry. This evidence concerns the gene CD8A and neoplasm.